Takeda Test Drives EMA’s Parallel Review Route For EU And Non-EU Markets
Company Submits Two Sets Of Applications For Evaluation Of Its Dengue Vaccine To CHMP
Executive Summary
A new evaluation route that the European Medicines Agency launched last year came at the right time for Takeda’s dengue vaccine candidate.
You may also be interested in...
Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension
Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.
Takeda Eyes Further Filings For Dengue Vaccine But Timings Unclear
With Qdenga’s US approval process moving ahead with the granting of a Priority Review and the dengue vaccine's first market launch, in Indonesia, expected early next year, Takeda has recently referred to plans to expand the product into other countries as well. But precise timings as yet remain unclear.
Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets
Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.